Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

GUIDE.MRD GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

Coordinator
Universitaetsklinikum Hamburg-Eppendorf, Germany
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€17.7m
Total cost
€34.4m
Partners
35 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101112066

What the project is doing

In the project's own words, from its summary on CORDIS.

Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved outcomes depends on clinical implementation of novel diagnostic technologies. For most cancer types the risk-features used to select individuals for post-operative adjuvant multimodal therapy are suboptimal, where many patients are overtreated and others undertreated. Liquid biopsy has opened a new diagnostic avenue to detect and monitor minimal residual disease (MRD) in individual cancer patients, especially for selecting patients for multi-modal therapies post-operatively.

However, despite many circulating tumor DNA (ctDNA) diagnostics being developed there is a lack of standardization, harmonization, and robust data to demonstrate clinical validity. GUIDE.MRD is a consortium of leading academics, technology companies, pharmaceutical companies, and experts in multi-stakeholder engagements. Together, we will tackle the critical questions by developing reference standards for ctDNA diagnostics, clinically validate promising ctDNA diagnostics and develop data to guide the use of multi-modal therapies with a non-invasive diagnostic test.

With robust engagement with regulatory authorities, payers and importantly patients themselves, we will develop recommendations and guidelines based on objective data to use ctDNA diagnostics to guide multi-modal therapy selection to improve patient outcomes.

Who is involved

OrganisationCityCountryRole
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyCoordinator
Medizinische Universitat GrazGrazAustriaParticipant
Digestive Cancers Europe DiceBruxelles / BrusselBelgiumParticipant
Synergist ServicesBruxelles / BrusselBelgiumParticipant
The SynergistBruxelles / BrusselBelgiumParticipant
Amgen (europe) GmbHZugSwitzerlandParticipant
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Lung Cancer Europe LuceBernSwitzerlandAssociatedpartner
Abbvie Deutschland GmbH & Co KgWiesbadenGermanyAssociatedpartner
Bristol-Myers Squibb GmbH & Co. KgaaMunichGermanyAssociatedpartner
Lungenclinic Grosshansdorf GmbHGrosshansdorfGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Aarhus UniversitetshospitalAarhusDenmarkParticipant
Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos IiiMadridSpainParticipant
Bristol-Myers Squibb SASRueil-MalmaisonFranceAssociatedpartner
Centre Hospitalier Universitaire De NiceNiceFranceParticipant
Centre Hospitalier Universitaire MontpellierMontpellierFranceParticipant
Innovation Acta SRLSienaItalyParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Bristol-Myers Squibb B.V.UtrechtNetherlandsAssociatedpartner
Asociatia Centrul Pentru Inovatie in MedicinaBucharestRomaniaParticipant
Karolinska InstitutetStockholmSwedenParticipant
Region StockholmStockholmSwedenParticipant
Astrazeneca UK LimitedCambridgeUnited KingdomParticipant
Horizon Discovery LimitedCambridgeUnited KingdomParticipant
Illumina Cambridge LimitedCambridgeUnited KingdomParticipant
Labcorp Early Development Laboratories LimitedHarrogateUnited KingdomParticipant
Abbvie IncNorth Chicago IlUnited StatesParticipant
Amgen IncNewbury ParkUnited StatesAssociatedpartner
AstraZeneca Pharmaceuticals LPWilmingtonUnited StatesAssociatedpartner
Bristol-Myers Squibb Company CorpNew YorkUnited StatesParticipant
E.r. Squibb & Sons LlcNew BrunswickUnited StatesAssociatedpartner
Illumina Inc.San DiegoUnited StatesAssociatedpartner
Lgc Clinical Diagnostics IncMilfordUnited StatesParticipant
Personal Genome Diagnostics Inc.BaltimoreUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI